NaomiS(Haas)BalzerMD

Oncology • Philadelphia, PA

Genitourinary Oncology, Hematologic Oncology, Melanoma

Director, Prostate and Kidney Cancer Program; Associate Professor of Medicine at the Hospital of the University of Pennsylvania

Join to view full profile

Dr. Balzer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Balzer's full profile

Already have an account?

Office
3400 Civic Center Blvd
Philadelphia, PA 19104
Phone+1 215-615-5858

Fax+1 215-349-8144

Education & Training

Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
Abington Memorial HospitalResidency, Internal Medicine, 1985 - 1988
Northeast Ohio Medical UniversityClass of 1985

Certifications & Licensure

PA State Medical License 1986 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Bryostatin 1 in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 1999 Jun 01
Completed
Phase 2
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer Start of enrollment: 2002 Oct 01
Completed
Phase 3
Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma Start of enrollment: 2004 Feb 24
Completed
Phase 2
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery Start of enrollment: 2006 Apr 24
Completed
Phase 3
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery Start of enrollment: 2010 Sep 17
Completed
Phase 2
Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed Start of enrollment: 2016 Jul 25
Active, not recruiting
Phase 2
CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer Start of enrollment: 2017 Mar 08
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal C...
Pedro Barata, Catherine Tangen, Melissa Plets, Ian M Thompson Jr, Vivek Narayan
Journal of Clinical Oncology. 2024-11-20
1 citations
Coronary Microvascular Dysfunction in Men with Prostate Cancer Receiving Androgen-Deprivation Therapy.
Erin Welch, Marie A Guerraty, Biniyam G Demissei, Naomi Haas, Samuel Takvorian
Clinical Genitourinary Cancer. 2024-08-01
9 citations
Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma.
Toni K Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Stefan Symeonides
The Oncologist. 2024-02-02

Press Mentions

Three Kidney Cancer Experts to Receive Awards at 2024 IKCS: North AmericaSeptember 27th, 2024
Presents State of the Science SummitSeptember 20th, 2017
RCC Advances Shake up Drug ChoicesApril 7th, 2017
Join now to see all